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Background/Aims: Many candidate gene studies have 
revealed that polymorphisms of the 5’-flanking controlled 
SERT gene linked polymorphic region (5HTT-LPR) gene and 
G-protein β3 C825T gene might be associated with func-
tional dyspepsia (FD) and irritable bowel syndrome (IBS). 
This study was performed to investigate polymorphisms 
of the 5HTT-LPR gene and G-protein β3 C825T gene in FD 
and IBS in Korean children. Methods: In total, 102 patients 
with FD, 72 patients with IBS based on the Rome III criteria 
and 148 healthy controls without gastrointestinal symp-
toms were included in the study to analyze 5HTT-LPR and 
G-protein β3 C825T polymorphisms. Results: 5HTT-LPR 
genotype analysis revealed no signiﬁ  cant differences in FD 
and IBS patients compared with controls. The GNβ3 C825T 
genotype distribution for CC, CT, and TT was 23.6%, 53.4%, 
and 23.0% in controls, 36.3%, 38.2%, and 25.5% in FD and 
37.5%, 38.9%, and 23.6% in IBS, respectively. The CC geno-
type was more common in FD and IBS patients than controls 
(p<0.05). When the IBS patients were grouped according 
to IBS subtypes, CC genotype GNβ3 C825T was common in 
diarrhea-dominant IBS, and the TT genotype was common 
in constipation-dominant IBS (p<0.05). Conclusions: The 
CC genotype of G-protein β3 C825T may be associated with 
FD and diarrhea-predominant IBS. The TT genotype may be 
associated with constipation-predominant IBS. (Gut Liver 
2012;6:223-228)
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INTRODUCTION
Functional gastrointestinal disorder (FGID) is characterized 
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by structural and biochemical dysfunctions and has various and 
repetitive gastrointestinal symptoms without definite patho-
physiology. Therefore, it can only be diagnosed by characteristic 
symptoms or after excluding other diseases with laboratory 
results or procedures such as endoscopy.
1 Functional dyspepsia 
(FD) and irritable bowel syndrome (IBS) are well known pa-
thologies of FGID; both are highly prevalent in up to 25% of 
the population. Many studies of patients with FD and IBS have 
shown functional disturbances in gastrointestinal motor and 
sensory function. The etiology of FGID is assumed to be associ-
ated with infection, alterations of the immune system or intes-
tinal motility, or even psychiatric factors.
2,3 Recently, genetic 
approaches have made forward steps to identify the etiology. 
For example, many family aggregation and twin studies have 
reported genetic components that might be associated with 
FGID, although common environmental factors they might also 
share must be considered.
4,5 
A number of receptors have been proven to have altered 
functions in FGID, including cholecystokinin, serotonin trans-
porter (SERT) protein, heterotrimeric G-proteins, and interleukin 
(IL)-10. Among many candidate genes, the SERT protein gene is 
the best known in IBS, and there is a part called the 5’-flanking 
controlled SERT gene linked polymorphic region (5HTT-LPR), 
which reveals the SERT protein.
6 Serotonin (5-HT) plays a key 
role in modulating sensory and motor functions in the gastro-
intestinal tract. In particular, 5-HT type 3 receptors are known 
to mediate the postprandial colonic motor responses, cramping, 
diarrhea, and constipation in IBS patients. A prior study in Ko-
rea demonstrated SS subtype of SERT is significantly associated 
with diarrhea-predominant IBS in adults.
7
G-protein is another emerging candidate gene to study and 
is essential for stimulus-response coupling in the intracellular 
system; it is involved in ion channels and protein kinases. It is 224  Gut and Liver, Vol. 6, No. 2, April 2012
also a main mediator in controlling a signal transport into the 
cellular system. G-Protein β3 C825T polymorphism could lead 
to an altered signal transduction response and functional abnor-
mality such as changes of sensory function or motility associ-
ated with FGID.
8 GNβ3 has a single nucleotide polymorphism in 
C825T, which converts cytosine to thymidine, and allele shifting 
was performed according to each subtype, each of which has a 
different activity. With even a small change, GNβ3 C825T CC 
type plays a role in the reduction of signaling, subsequently 
alters gastrointestinal sensation and motility, and is therefore 
considered to be associated with FD or IBS.
9 TT type potentiates 
G-protein activity and cellular reactions that can cause cardio-
vascular disease, hypertension, metabolic disease, and affective 
disorder.
10
In this study, we tried to investigate that the polymorphisms 
of SERT and GNβ3 C825T would be associated with IBS and FD 
in Korean children. 
MATERIALS AND METHODS
1. Study subjects
Patients aged 4 to 18 years who visited outpatient clinic of 
the Department of Pediatrics at Eulji Medical Center were re-
cruited consecutively from November 2009 to July 2010. All 
patients underwent validated questionnaires regarding gastro-
intestinal symptoms according to Rome III criteria. The study 
subjects were diagnosed as IBS or FD by their responses to 
questionnaire.
11 In children and adolescents, FD is defined as 
persistent or recurrent pain or discomfort centered in the up-
per abdomen (above the umbilicus) not relieved by defecation 
or associated with the onset of a change in stool frequency or 
stool form. IBS is defined as abdominal discomfort or pain as-
sociated with 2 or more of the followings at least 25% of the 
time; improved with defecation, onset associated with a change 
in frequency of stool, onset associated with a change in form 
of stool. Both criteria are fulfilled when the symptom occurs at 
least once per week for at least 2 months before diagnosis.
11 
For each participant, detailed history taking, physical exami-
nation, and if necessary, further evaluation such as blood tests, 
abdominal ultrasonography, and upper gastrointestinal endos-
copy were performed to distinguish FGIDs from other organic 
causes. Exclusion criteria included significant upper gastrointes-
tinal diseases such as gastrointestinal bleeding, persistent vomit-
ing, peptic ulcer disease and reflux esophagitis. Severe systemic 
diseases that may induce gastrointestinal symptoms, lactase 
deficiency, a history of previous major abdominal surgery and 
developmental disability were also excluded. Healthy children 
who visited the clinic for screening purposes without gastroin-
testinal symptoms were invited to participate as a control group. 
Finally, 174 FGID patients (72 with IBS and 102 with FD) and 
148 control subjects participated in this study.
All patients were provided with written informed consent for 
the study. This prospective study was approved by the Insti-
tutional Review Board of Eulji University School of Medicine, 
which confirmed that the study was in accordance with the 
ethical guidelines of the Helsinki Declaration.
2. Methods
1) Genomic DNA preparation
Genomic DNA was prepared from peripheral blood samples 
using a nucleic acid isolation device, QuickGene-mini80 (Fujif-
ilm, Tokyo, Japan). 
2) Genotyping for GNβ3 C825T 
The genotyping was screened using single base primer ex-
tension assay using ABI PRISM SNaPShot Multiplex kit (ABI, 
Foster City, CA, USA) according to manufacturer’s recommen-
dation. The DNA fragment amplification was conducted with 
the sense primer 5’-TGGCACGTGGTATGTGTTG-3’ and the anti-
sense primer 5’-GGAACCAAGGGGTACTGGA-3’.
Briefly, the genomic DNA flanking the interested single-nucleo-
tide polymorphism was amplified with polymerase chain reaction 
(PCR) with Forward and Reverse primer pairs and standard PCR 
reagents in 10 μL reaction volume, containing 10 ng of genomic 
DNA, 0.5 pM of each oligonucleotide primer, 1 μL 10x PCR buffer, 
250 μM dNTP (2.5 mM each) and 0.25 unit i-StarTaq DNA Poly-
merase (5 unit/μL) (iNtRON Biotechnology, Seongnam, Korea). The 
PCR reactions were carried out as follows: 10 minutes at 95
oC for 
1 cycle, and 35 cycles on 95
oC for 30 seconds, 60
oC for 1 minute, 
72
oC for 1 minute followed by 1 cycle of 72
oC for 10 minutes. After 
amplification, the PCR products were treated with 1 unit each of 
shrimp alkaline phosphatase (SAP) (USB Co., Cleveland, OH, USA) 
and exonuclease I (USB Co.) at 37
oC for 75 minutes and 72
oC for 15 
minutes to purify the amplified products. One microliter of the pu-
rified amplification products were added to a SNaPshot Multiplex 
Ready reaction mixture containing 0.15 pmols of genotyping prim-
er for primer extension reaction. The primer extension reaction was 
carried out for 25 cycles of 96
oC for 10 seconds, 50
oC for 5 seconds, 
and 60
oC for 30 seconds. The reaction products were treated with 
1 unit of SAP at 37
oC for 1 hour and at 72
oC for 15 minutes to re-
move excess fluorescent dye terminators. One microliter of the final 
reaction samples containing the extension products were added to 
9 μL of Hi-Di formamide (ABI). The mixture was incubated at 95
oC 
for 5 minutes, followed by 5 minutes on ice and then analyzed by 
electrophoresis in ABI Prism 3730xl DNA analyzer. Analysis was 
carried out using Genemapper software (version 4.0; Applied Bio-
systems, Foster City, CA, USA). 
3) Genotyping for SERT
PCR was carried out in a total volume of 10 μL containing 10 
ng genomic DNA, 0.5 uM each of the sense (5’-GGCGTTGCC-
GCTCTGAATGC-3’) and antisense (5’-GAGGGACTGAGCTG-
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phosphates (dATP, dCTP, dGTP, dTTP), 0.25 unit i-StarTaq DNA 
Polymerase. To amplify the fragment, the 500 mM of betaine 
was added to the PCR system. Amplification conditions con-
sisted of an initial denaturing step at 95
oC followed by 35 cycles 
of 95
oC for 30 seconds, 65
oC for 1 minute and 72
oC for 1 min-
ute. This was followed by a final extension step at 72
oC for 10 
minutes. To detect the amplified DNA fragment, we analyzed 2 
μL of the reaction mixtures on a 3% agarose gel (ReadyAgarose 
96 plus 3% TBE Gel; Bio-Rad, Richmond, CA, USA).
4) Statistical analysis
We calculated allele and genotype frequencies (%) for each 
polymorphism among controls and each group of patients. Dif-
ferences of these frequencies were compared using chi-square 
test or Student’s t-test. A logistic regression analysis was per-
formed to test the association between genotype distribution 
of polymorphism for SERT and Gnβ3 C825T and diseases of 
FD and IBS. The odds ratio (OR) and 95% confidence intervals 
(CI) were calculated by logistic regression. SPSS for Windows 
version 13.0 (SPSS Inc., Chicago, IL, USA) was used for statisti-
cal analysis. Statistical significance was determined as p-value 
<0.05.
RESULTS
Characteristics of study subjects are shown in Table 1. Sev-
enty-two IBS patients and 102 FD patients who met the Rome 
III criteria were enrolled. There was no statistical difference with 
respect to age and gender among IBS, FD and control group 
(Table 1). Of the 72 IBS cases, 61% had diarrhea-predominant 
IBS, 24% had constipation-predominant IBS and 15% had alter-
nating- type IBS. 
1. IBS vs controls genotype distribution
The 5HTT-LPR genotype distribution for LL, LS, and SS was 
1.4%, 37.5%, and 61.1%. SS type was more common in IBS 
group than in controls, but the difference was not significant.
The genotype frequencies for GNβ3 C825T polymorphism 
was 37.5%, 38.9% and 23.6% for CC, CT, and TT. CC genotype 
was more common than in controls (p<0.05) (OR, 1.937; 95% 
CI, 1.053 to 3.563) (Table 2).
2. FD vs controls genotype distribution
The 5HTT-LPR genotype distribution for LL, LS, and SS was 
3.4%, 37.2%, 59.5% in controls and 8.8%, 27.5%, 63.7% in FD. 
LL and SS types were more common in FD group than in con-
trols, but the difference was not significant. 
The GNβ3 C825T genotype distribution for CC, CT, and TT 
was 23.6%, 53.4%, 23.0% in controls and 36.3%, 38.2%, 25.5% 
in FD. CC genotype was more common than in controls (p<0.05) 
(OR, 1.838; 95% CI, 1.056 to 3.197) (Table 2).
3. IBS-subtype genotype distribution
Genotype frequency differences were not observed for 5HTT-
LPR polymorphism between the IBS subtypes and controls. CC 
genotype of GNβ3 C825T was common in diarrhea predominant 
IBS (p<0.05) (OR, 2.69; 95% CI, 1.330 to 5.441) and TT geno-
type was common in constipation predominant IBS (p<0.05) (OR, 
2.98; 95% CI, 1.068 to 8.319) (Table 3).
DISCUSSION
Several polymorphisms for genes have been studied to iden-
tify the etiology of functional gastrointestinal diseases, and 
there are several candidate genes such as SERT gene, G-protein, 
IL-10, tumor necrosis factor (TNF)-α, and adrenalin that play 








  Male  81 (54.7)  32 (44.4)  32 (31.3) 
  Female  67 (45.3)  40 (55.6)  70 (68.7) 
Male:Female* 1.2:1 0.8:1 0.5:1 
Age, mean±SD, yr*  10.8±3.9  13.3±3.7  11.2±3.6 
Data are presented as number (%).
IBS, irritable bowel syndrome; FD, functional dyspepsia; SD, standard 
deviation.
*p>0.05.
Table 2. Polymorphisms of SERT and the GNβ3 C825T Gene among 








5HTT-LPR polymorphism, n (%) 
  LL  5 (3.4)  1 (1.4)  9 (8.8)  
  LS  55 (37.2)  27 (37.5)   28 (27.5)  
  SS  88 (59.5)  44 (61.1)  65 (63.7) 
  L-allele   65   29    46
  S-allele 231 115         158     
GNβ3 C825T polymorphism, n (%)
  CC  35 (23.6)  27 (37.5)*     37 (36.3)
†
  CT  79 (53.4)  28 (38.9)    39 (38.2)
  TT  34 (23.0)  17 (23.6)  26 (25.5) 
  C-allele 149 82 113
  T-allele 147 62   91 
SERT, serotonin transporter; IBS, irritable bowel syndrome; FD, func-
tional dyspepsia; 5HTT-LPR, 5’-flanking controlled SERT gene linked 
polymorphic region.
*χ
2=7.639, p=0.022 (FD vs controls), odds ratio (95% confidence in-
terval) for CC vs non-CC genotypes: 1.838 (1.056-3.197); 
†χ
2=6.435, 
p=0.040 (IBS vs controls), odds ratio (95% confidence interval) for CC 
vs non-CC genotypes: 1.937 (1.053-3.563).226  Gut and Liver, Vol. 6, No. 2, April 2012
important roles in the pathophysiology of FGID.
12 This study 
aimed to investigate that polymorphism of SERT and G-protein 
was differently expressed in children with FGID. SERT gene 
is most frequently studied gene in IBS, and three different 
polymorphic sites have been found. The function of SERT in 
the gastrointestinal tract is similar to its function in the brain. 
SERT polymorphism occurs as a 44-base-pair insertion or dele-
tion of the SERT gene. 5HTT-LPR of the 5’flanking controlling 
site, variable number tandem repeats in the second intron, and 
rs25531 have thus far been studied. In particular, the S subtype 
of 5HTT-LPR is known to have longer serotonin action time 
compared to the L subtype because of reduced transcription 
ability against SERT.
13 Yeo et al.
14 reported that the SS type 
was associated with diarrhea-predominant IBS, but other stud-
ies conducted in Western countries showed that there was no 
relationship between IBS and 5HTT-LPR.
15,16 Our study showed 
lack of association between 5HTT-LPR genotypes and all types 
of IBS. The discrepancies may be due to racial or regional dif-
ferences and we can assume that although these polymorphisms 
may have clinical consequences, their effects are not significant. 
Previous studies with FD patients showed that there was no 
close relationship between SERT and FD.
12,17 Our data was con-
sistent with previous data and there were no definite differences 
between this polymorphism and FD. 
G-proteins are known as key receptors that comprise about 
80% of cellular receptors and play an important role in trans-
porting signals into the cell. Signal transporting is regulated 
through changes of G-protein.
18 Holtmann et al.
19 studied 67 pa-
tients with epigastric pain of unknown origin and reported that 
homozygous GNβ3 C825T CC genotype was associated more 
strongly with FD than controls. Camilleri et al.
12 reported that 
homozygous CC or TT genotypes are associated with meal unre-
lated dyspepsia due to fluctuations of G-protein activity.  But it 
is unlikely that subjects presenting with same dyspepsia pheno-
type group reveal the association with both alleles. Other studies 
have reported that the TT type was related to FD.
17,20 These con-
trasting findings may be due to differences of genotype com-
position in different countries, which comprise different racial 
groups. In our study, the CC genotype was more prevalent in FD 
group than the control group and considered statistically signif-
icant (p<0.05). Our result of FD patients was coincided with that 
of Holtmann et al.
9 CC genotype might inhibit the translation of 
G-protein and also the activity against neurotransmitters such 
as serotonin at 5HT4 receptors which stimulates motor function 
and may cause gastric motility disorder such as gastroparesis. 
Previous studies in Western countries have reported that 
there was no correlation between GNβ3 C825T and IBS.
21,22 But 
recently a study with Korean adults showed that GNB3 825T 
allele might be associated with IBS with constipation and in a 
Greek study TT genotype and T allele of GNβ3 showed signifi-
cant association with IBS.
23,24
We observed CC type was more common in overall IBS than 
in controls. When the IBS patients were divided into subgroups 
of diarrhea dominant IBS, constipation dominant IBS and al-
ternating type IBS, CC genotype was associated with diarrhea 
dominant IBS and TT genotype was associated with constipa-
tion dominant IBS. GNβ3 T allele can be associated with vis-
ceral hypersensitivity as a consequence of the increased signal 
transduction upon G-protein-coupled receptors activation and 
may be related with symptom generation in IBS.
25 Alternately, 
CC genotype is known to result in reduced G protein translation. 
Besides subjects with CC genotype may have decreased immune 
response to infection and thus needs prolonged period of recov-
ery from any infection. This may act as predisposing factor to 
Table 3. Polymorphisms of SERT and GNβ3 C825T among the Controls and Each of the IBS Subtypes
Genotype  Controls (n=148) D-IBS (n=44) C-IBS (n=17) A-IBS (n=11)
5HTT-LPR polymorphism, n (%)
  LL 5 (3.4) 0 (0.0) 0 (0.0) 1 (9.1)
  LS 55 (37.2) 19 (43.2) 7 (41.2) 4 (36.4)
  SS 88 (59.5) 25 (56.8) 10 (58.8) 6 (54.5)
  L-allele 65 19 7 6
  S-allele 231 69 27 16
GNβ3 C825T polymorphism, n (%)
  CC 35 (23.6) 20 (45.5)* 2 (11.8) 5 (45.4)
  CT 79 (53.4) 17 (38.6) 7 (41.2) 4 (36.4)
  TT 34 (23.0) 7 (15.9) 8 (47.1)
† 2 (18.2)
  C-allele 149 57 11 14
  T-allele 147 31 23 10
SERT, serotonin transporter reuptake gene; IBS, irritable bowel syndrome; D-, diarrhea dominant; C-, constipation dominant; A-, alternating con-
stipation and diarrhea; 5HTT-LPR, 5’-flanking controlled SERT gene linked polymorphic region.
*χ
2=8.280, p=0.016 (control vs D-IBS), odds ratio (95% confidence interval) for CC vs non-CC genotypes: 2.69 (1.330-5.441); 
†χ
2 =7.633, p=0.006 
(control vs C-IBS), odds ratio (95% confidence interval) for TT vs non-TT genotypes: 2.98 (1.068-8.319).Park CS, et al: Candidate Genotypes in Children with FGID  227
visceral hypersensitivity.
9
Our data are not consistent with previous studies that GNβ3 
CC genotype was not associated with IBS. The different result 
between previous studies and our study are might be due to ra-
cial difference or small number of patients tested.
There are some limitations to this study. The sample size was 
not large enough to identify possible genetic associations. How-
ever, to our knowledge, this is the first study to demonstrate ge-
netic polymorphisms in children with FGID. If there are genetic 
factors contributing to the manifestation of FGID, investigation 
in children will be more important than in adults. If we can as-
sume that people develop FGID before they show clinical symp-
toms, genetic testing may facilitate diagnosis to save economic 
costs for invasive procedures to discover the cause of gastroin-
testinal symptoms from the onset. 
FGIDs are common in children, accounting for 5% to 10% 
of pediatric primary practice consultation and 25% of pediatric 
gastroenterology consultation.
26 Despite the high prevalence 
and effects of FGIDs, no evidence-based guidelines for its evalu-
ation and treatment exist. If FGIDs are associated with genetic 
factors, and if some children have predispositions of FGIDs, the 
facts would affect their adult’s life. In this point, the follow-up 
study would be important. The relation of treatment response or 
prognosis of FGIDs with the subtypes of polymorphism is also 
necessary.
In conclusion, the present study suggests that there is signifi-
cant correlation between polymorphisms of the G-protein β3 
C825T genotypes and FD. FD might result partly from genetical-
ly altered G-protein receptor coupling. Additional environmen-
tal or genetic background might be involved. The association of 
SERT genotype with FD or IBS phenotype compared with con-
trols was not statistically significant. For the future, there needs 
to be more data from more diverse areas and a larger sample to 
verify and analyze the possible involvement of candidate genes 
that influence the development of FGIDs.
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